Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00635154 · OUTCOME

Duration of Response

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma · Source last updated 2018-06-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From first documentation of response to progression or last follow-up (up to 5 years)

What was measured

Duration of response is defined for all evaluable participants (receiving Anakinra alone or in combination with Dexamethasone) who have achieved an objective response as the date at which the participants status was first noted to be MR or better to the date progression is documented or the date of last follow-up.

Analysis population: Participants (receiving Anakinra alone or in combination with Dexamethasone) who achieved a MR or better were analyzed.

Groups in this outcome

Anakinra With/Without Dexamethasone

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Anakinra With/Without Dexamethasone15

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Anakinra With/Without Dexamethasone41.9Not reported14.6NAThe upper bound for the confidence interval has not been attained.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The upper bound for the confidence interval has not been attained.
        group Id
        OG000
        lower Limit
        14.6
        upper Limit
        NA
        value
        41.9
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
Duration of response is defined for all evaluable participants (receiving Anakinra alone or in combination with Dexamethasone) who have achieved an objective response as the date at which the participants status was first noted to be MR or better to the date progression is documented or the date of last follow-up.
dispersion Type
95% Confidence Interval
groups
  1. id
    OG000
    title
    Anakinra With/Without Dexamethasone
param Type
MEDIAN
population Description
Participants (receiving Anakinra alone or in combination with Dexamethasone) who achieved a MR or better were analyzed.
reporting Status
POSTED
time Frame
From first documentation of response to progression or last follow-up (up to 5 years)
title
Duration of Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice